Pentoxifylline treatment and penile calcifications in men with Peyronie's disease

Asian Journal of Andrology

Volumn 13, Issue 2, 2011, Pages 322-325

  Smith, James F ^a   Shindel, Alan W ^a   Huang, Yun Ching ^a   Clavijo, Raul I ^a   Flechner, Lawrence ^a   Breyer, Benjamin N ^a   Eisenberg, Michael L ^a   Lue, Tom F ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

penile calcifications; pentoxifylline; Peyronie's disease; treatment

Indexed keywords

ALPHA TOCOPHEROL; CALCIUM; PENTOXIFYLLINE;

ADULT; AGED; ARTICLE; CALCIFICATION; COHORT ANALYSIS; DEMOGRAPHY; DRUG DOSE INCREASE; ECHOGRAPHY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PENIS CALCIFICATION; PEYRONIE DISEASE; QUESTIONNAIRE; RETROSPECTIVE STUDY; SEXUAL FUNCTION; STATISTICAL ANALYSIS; TREATMENT DURATION;

ADULT; AGED; CALCINOSIS; COHORT STUDIES; HUMANS; MALE; MIDDLE AGED; PENILE INDURATION; PENIS; PENTOXIFYLLINE; PHOSPHODIESTERASE INHIBITORS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VITAMIN E;

EID: 79952402829     PISSN: 1008682X     EISSN: 17457262     Source Type: Journal    
DOI: 10.1038/aja.2010.117     Document Type: Article

References (28)

1. Mulhall JP, Creech SD, Boorjian SA, Ghaly S, Kim ED et al. Subjectiveand objective analysisof theprevalenceof Peyronie'sdisease in a population of men presentingfor prostate cancer screening. J Urol 2004; 171: 2350-3. (Pubitemid 38625468)
2. Schwarzer U, Sommer F, Klotz T, Braun M, Reifenrath B et al. The prevalence of Peyronie's disease: results of a largesurvey. BJU Int 2001; 88: 727-30.
3. Safarinejad MR. Therapeutic effects of colchicine in the management of Peyronie's disease: a randomizeddouble-blind, placebo-controlledstudy. Int J Impot Res 2004; 16:238-43. (Pubitemid 38858956)
4. Hellstrom WJ, Kendirci M, Matern R, Cockerham Y, Myers L et al. Single-blind, multicenter, placebo controlled, parallel study to assess the safety and efficacy of intralesional interferon alpha-2B for minimally invasive treatment for Peyronie's disease. J Urol 2006; 176: 394-8. (Pubitemid 43833173)
5. Inal T, Tokatli Z, Akand M, Ozdiler E, Yaman O. Effectof intralesional interferon-alpha 2b combined with oral vitamin E for treatment of early stage Peyronie's disease: a randomized and prospective study. Urology 2006; 67: 1038-42. (Pubitemid 43956407)
6. Cavallini G, Biagiotti G, Koverech A, Vitali G. Oral propionyl-L- carnitine and intraplaque verapamil in the therapy of advanced and resistant Peyronie's disease. BJU Int 2002; 89: 895-900. (Pubitemid 34535423)
7. Greenfield JM, Shah SJ, Levine LA. Verapamil versus saline in electromotive drug administration for Peyronie's disease: a double-blind, placebo controlledtrial. JUrol 2007; 177: 972-5. (Pubitemid 46216345)
8. Rehman J, Benet A, Melman A. Useof intralesional verapamil to dissolve Peyronie's disease plaque: a long-term single-blind study. Urology 1998; 51: 620-6. (Pubitemid 28186217)
9. Safarinejad MR, Hosseini SY, Kolahi AA. Comparison of vitamin E and propionyl-L-carnitine, separately or in combination, in patients with early chronic Peyronie's disease: a double-blind, placebo controlled, randomized study. J Urol 2007; 178: 1398-403; discussion 403. (Pubitemid 47368421)
10. Pryor J, Akkus E, Alter G, Jordan G, Lebret Tet al. Peyronie'sdisease. J Sex Med 2004; 1: 110-5.
11. Aviado DM, Porter JM. Pentoxifylline: a new drug for the treatment of intermittent claudication. Mechanism of action, pharmacokinetics, clinical efficacy and adverse effects. Pharmacotherapy 1984; 4: 297-307. (Pubitemid 15181910)
12. Mc Carty MF. Interleukin-6asacentral mediatorof cardiovascularriskassociated with chronic inflammation, smoking, diabetes, and visceral obesity: down-regulation with essentialfattyacids, ethanol and pentoxifylline. Med Hypotheses 1999; 52: 465-77.
13. Noel C, Copin MC, Hazzan M, Labalette M, Susen S et al. Immunomodulatoryeffectof pentoxifyllineduring human allograft rejection: involvementof tumor necrosisfactor-alpha and adhesion molecules. Transplantation 2000; 69: 1102-7.
14. Tittelbach J, Graefe T, Wollina U. Painful ulcers in calciphylaxis\ combined treatment with maggot therapy and oral pentoxyfillin. J Dermatolog Treat 2001; 12: 211-4. (Pubitemid 34033265)
15. Boldt J, Brosch C, Lehmann A, Haisch G, Lang J et al. Prophylactic use of pentoxifylline on inflammation in elderly cardiac surgery patients. Ann Thorac Surg 2001; 71: 1524-9.
16. Delanian S, Porcher R, Balla-Mekias S, Lefaix JL. Randomized, placebo-controlled trial of combined pentoxifyllineandtocopherol for regressionof superficial radiation-induced fibrosis. J Clin Oncol 2003; 21: 2545-50. (Pubitemid 46606336)
17. Saad SY, Najjar TA, Alashari M. Roleof non- selectiveadenosinereceptorblockadeand phosphodiesterase inhibition in cisplatin-induced nephrogonadal toxicity in rats. Clin Exp Pharmacol Physiol 2004; 31: 862-7. (Pubitemid 40052310)
18. Rajfer J, Gore JL, Kaufman J, Gonzalez-Cadavid N. Casereport: avoidanceof palpable corporal fibrosisdueto priapism with upregulatorsof nitricoxide. J Sex Med 2006; 3 173-6.
19. Brant WO, Dean RC, Lue TF. Treatmentof Peyronie'sdiseasewith oral pentoxifylline. Nat Clin Pract Urol 2006; 3: 111-5; quiz 6.
20. Levine LA. Treatment of Peyronie's disease with intralesional verapamil injection. J Urol 1997; 158: 1395-9. (Pubitemid 27391205)
21. Jordan GH. The use of intralesional clostridial collagenase injection therapy for Peyronie'sdisease: a prospective, single-center, non-placebo-controlled study. J Sex Med 2008; 5: 180-7.
22. El-Sakka AI, Hassoba HM, Pillarisetty RJ, Dahiya R, Lue TF. Peyronie's disease is associated with an increase in transforming growth factor-beta protein expression. J Urol 1997; 158: 1391-4.
23. Vernet D, Nolazco G, Cantini L, Magee TR, Qian A et al. Evidence that osteogenic progenitor cells in the human tunica albuginea may originate from stem cells: implicationsfor Peyroniedisease. Biol Reprod 2005; 73: 1199-210. (Pubitemid 41698610)
24. Ng YY, Chen YM, Tsai TJ, Lan XR, Yang WC et al. Pentoxifylline inhibitstransforming growth factor-beta signaling and renal fibrosis in experimental crescentic glomerulonephritis in rats. Am J Nephrol 2009; 29: 43-53.
25. Bacher A, Eggensperger E, Koppensteiner R, Mayer N, Klimscha W. Pentoxifylline attenuates the increase in whole blood viscosity after transfusion. Acta Anaesthesiol Scand 2005; 49: 41-6. (Pubitemid 40214851)
26. Strano A, Davi G, Avellone G, Novo S, Pinto A. Double-blind, crossover study of the clinical efficacy and the hemorheological effects of pentoxifylline in patients with occlusive arterial diseaseof the lower limbs. Angiology1984; 35: 459-66. (Pubitemid 14066497)
27. Tarhan OR, Barut I, Sutcu R, Akdeniz Y, Akturk O. Pentoxifylline, a methyl xanthine derivative, reduces peritoneal adhesions and increases peritoneal fibrinolysis in rats. Tohoku J Exp Med 2006; 209: 249-55. (Pubitemid 43905557)
28. Davila HH, Ferrini MG, Rajfer J, Gonzalez-Cadavid NF. Fibrin asan inducerof fibrosis in thetunica albuginea of the rat: a newanimal model of Peyronie's disease. BJU Int 2003; 91: 830-8. (Pubitemid 36724070)